×
About 3,303 results

ALLMedicine™ Actinic Keratosis Center

Research & Reviews  912 results

Treatment of actinic keratosis: a systematic review.
https://doi.org/10.1007/s00403-022-02490-5
Archives of Dermatological Research; Worley B, Harikumar V et. al.

Dec 2nd, 2022 - Treatment of actinic keratoses (AKs) can help lower the risk of eventual skin cancer and address field pre-cancerization. This review compares the different therapeutic options for actinic keratosis. Databases used include Medline, EMBASE, Web of ...

Cutaneous Squamous Cell Carcinoma and Mortality in End-Stage Renal Disease.
https://doi.org/10.1016/j.amjms.2022.10.002
The American Journal of the Medical Sciences; Jung J, Waller JL et. al.

Nov 21st, 2022 - In the general population, cutaneous squamous cell carcinoma (cSCC) is associated with increased all-cause mortality. Transplant patients have been shown to have an increased risk of developing cSCC, and their cSCC is associated with an increased ...

Controlled register-based study of road traffic accidents in 12,651 Finnish cancer pati...
https://doi.org/10.1002/cam4.5444
Cancer Medicine; Huuskonen ML, Koistinen T et. al.

Nov 19th, 2022 - Little controlled evidence exists on road traffic accident (RTA) risk among patients diagnosed with cancer, while clinicians are often requested to comment their ability to drive. The aim of this study was to evaluate RTA risk in a population-base...

Reflectance confocal microscopy of facial neoplasms: Follicular involvement as a clue t...
https://doi.org/10.1111/cup.14353
Journal of Cutaneous Pathology; Shahriari N, Grant-Kels JM et. al.

Nov 3rd, 2022 - Facial skin is characterized by high density of follicles. Facial neoplasms may present overlapping clinical and dermoscopic findings. Our goal was to evaluate and compare, via reflectance confocal microscopy (RCM), follicular involvement in facia...

Imiquimod-induced hypertrophic lupus erythematosus-like reaction.
https://doi.org/10.5070/D328458526
Dermatology Online Journal; Safadi MG, Hassan S et. al.

Oct 20th, 2022 - Imiquimod is a topical immunomodulator that acts as an inducer of interferon (IFN)-a expression through Toll-like receptor (TLR)7 signaling with indications for the treatment of non-hyperkeratotic actinic keratosis of the face or scalp, superficia...

see more →

Guidelines  4 results

Management of actinic keratosis at specific body sites in patients at high risk of carc...
https://doi.org/10.1111/jdv.14753
Journal of the European Academy of Dermatology and Venere... Richard MA, Amici JM et. al.

Dec 14th, 2017 - Actinic keratoses (AK) arise on sun-exposed regions of the skin. If left untreated, AK may progress to invasive squamous cell carcinoma (SCC), although the rate of progression is low. A practical treatment algorithm for the treatment of AK in stan...

British Association of Dermatologists' guidelines for the care of patients with actinic...
https://doi.org/10.1111/bjd.15107
The British Journal of Dermatology; de Berker D, McGregor JM et. al.

Jan 18th, 2017 - British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017.|2017|de Berker D,McGregor JM,Mohd Mustapa MF,Exton LS,Hughes BR,|methods,methods,therapeutic use,therapeutic use,diagnosis,prevention & control...

Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - ...
https://doi.org/10.1111/jdv.13180
Journal of the European Academy of Dermatology and Venere... Werner RN, Stockfleth E et. al.

Sep 16th, 2015 - Actinic keratosis (AK) is a frequent health condition attributable to chronic exposure to ultraviolet radiation. Several treatment options are available and evidence based guidelines are missing. The goal of these evidence- and consensus-based gui...

Management of actinic keratosis: a practical report and treatment algorithm from AKTeam...
https://doi.org/10.1111/jdv.12434
Journal of the European Academy of Dermatology and Venere... Dréno B, Amici JM et. al.

Mar 13th, 2014 - Actinic keratoses (AK) are common photo-induced cutaneous lesions that may progress to invasive squamous-cell carcinoma and serve as a risk marker for skin cancer. Although numerous studies present the various therapeutic options for AK, publicati...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  193 results

Intralesional 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC
https://clinicaltrials.gov/ct2/show/NCT03370406

Oct 10th, 2022 - Squamous cell carcinoma (SCC) of the lower extremity is a distinct subset of cutaneous squamous cell carcinomas which tend to occur multiply in elderly women. In contrast, the majority of cutaneous SCCs occur on the head and neck, and in men more ...

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
https://clinicaltrials.gov/ct2/show/NCT05060237

Sep 27th, 2022 - The aim of the study is to evaluate the safety and tolerability of PDT for treatment of mild to severe actinic keratosis on the face and scalp in the expanded treatment field using 3 tubes of BF-200 ALA 10% gel (Ameluz®) in conjunction with the BF...

Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT04875026

Sep 19th, 2022 - Transient local skin reactions with topical Actinic Keratosis treatments such as 5-FluoroUracil (5-FU) often lead to non-adhesion from patients and thus to treatment failure. In regards to 5-FU treatment, these local reactions are related to the p...

Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients With Actinic Keratosis
https://clinicaltrials.gov/ct2/show/NCT05202860

Sep 14th, 2022 - Endeavoring to develop a new therapeutic and preventative strategy for patients with AK, this study aims to investigate the impact of 9-valent HPV vaccination on AK burden and -development over the course of 12 months. Seventy actinic keratosis (A...

Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis
https://clinicaltrials.gov/ct2/show/NCT03538951

Aug 23rd, 2022 - This Phase 2 clinical trial is a 3-part, open-label, multi-center study involving a non-occluded, daily topical dermal application of 1 of 2 strengths of VDA-1102 ointment for approximately 12 weeks (84 days) to an initial 2 cohorts of subjects. T...

see more →

News  189 results

Polypodium leucotomos found to reverse AK skin damage
https://www.mdedge.com/dermatology/article/257696/actinic-keratosis/polypodium-leucotomos-found-reverse-ak-skin-damage
Ted Bosworth

Sep 9th, 2022 - MILAN – Application of topical or both topical and oral polypodium leucotomos extract (PLE) was associated with significant reversal of adverse skin changes in patients with severe actinic keratoses (AKs) treated over 12 months, in a randomized, b.

Polypodium Leucotomos Found to Reverse AK Skin Damage
https://www.medscape.com/viewarticle/980541

Sep 9th, 2022 - MILAN — Application of topical or both topical and oral polypodium leucotomos extract (PLE) was associated with significant reversal of adverse skin changes in patients with severe actinic keratoses (AKs) treated over 12 months, in a randomized, b...

Right arm rash
https://www.mdedge.com/familymedicine/article/251881/dermatology/right-arm-rash
MDedge Family Medicine;

Feb 17th, 2022 - Common skin reactions to treatment with topical 5-FU for actinic keratosis include erythema, ulceration, and burning. In this case, however, the skin disruption opened the door to secondary impetigo.

Pink or red actinic keratoses signal more inflammation
https://www.mdedge.com/dermatology/article/249655/actinic-keratosis/pink-or-red-actinic-keratoses-signal-more-inflammation
Heidi Splete

Dec 8th, 2021 - Pinker or redder actinic keratoses (AKs) indicate greater inflammation, according to a retrospective study that analyzed images and histopathology slides of 49 actinic keratosis lesions. Data suggest that up to 65% of squamous cell carcinomas (SCC.

Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma
https://www.onclive.com/view/ripretinib-demonstrates-impressive-efficacy-durability-in-heavily-pretreated-kit-mutated-melanoma

Dec 4th, 2021 - The efficacy seen with ripretinib (Qinlock) in patients with KIT-mutated melanoma was higher than has been previously reported, according to Filip Janku, MD, PhD. Furthermore, the switch-control tyrosine kinase inhibitor (TKI) has elicited durable...

see more →

Patient Education  14 results see all →